• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.

作者信息

Verma Amit, Steidl Ulrich

机构信息

Department of Medicine (Oncology), Division of Hemato-Oncology; the Department of Developmental and Molecular Biology; the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; and the Albert Einstein Cancer Center, Albert Einstein College of Medicine/Montefiore Medical Center, New York, New York, USA.

Department of Cell Biology; the Department of Medicine (Oncology), Division of Hemato-Oncology; the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; and the Albert Einstein Cancer Center, Albert Einstein College of Medicine/Montefiore Medical Center, New York, New York, USA.

出版信息

Nat Med. 2015 Feb;21(2):113-4. doi: 10.1038/nm.3796.

DOI:10.1038/nm.3796
PMID:25654599
Abstract
摘要

相似文献

1
A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.一种针对急性髓系白血病中突变异柠檬酸脱氢酶的合成致死方法。
Nat Med. 2015 Feb;21(2):113-4. doi: 10.1038/nm.3796.
2
IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.IDH1/2 突变与 BCL-2 依赖性：AML 盔甲上的意外裂痕。
Cancer Cell. 2015 Mar 9;27(3):323-5. doi: 10.1016/j.ccell.2015.02.013.
3
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.异柠檬酸脱氢酶1和2突变在急性髓系白血病中诱导对BCL-2的依赖性。
Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19.
4
Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia.难治性急性髓性白血病患者接受BCL2抑制剂治疗后获得性BCR-ABL1融合和IDH1克隆进化
Leuk Res. 2021 Jan;100:106494. doi: 10.1016/j.leukres.2020.106494. Epub 2020 Dec 15.
5
Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.S100A8和S100A9的表达升高与急性髓系白血病（AML）对BCL-2抑制剂维奈托克的耐药性相关。
Leukemia. 2019 Oct;33(10):2548-2553. doi: 10.1038/s41375-019-0504-y. Epub 2019 Jun 7.
6
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.HOX 基因表达可预测急性髓系白血病对 BCL-2 抑制的反应。
Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.
7
Forecast: rough seas for leukemia.预测：白血病患者前路坎坷。
Cancer Discov. 2014 Mar;4(3):278-9. doi: 10.1158/2159-8290.CD-14-0084.
8
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.艾伏尼布诱导的分化增强了异柠檬酸脱氢酶2（IDH2）突变的急性髓系白血病对维奈克拉的敏感性。
Leukemia. 2022 Mar;36(3):869-872. doi: 10.1038/s41375-021-01468-y. Epub 2021 Nov 6.
9
[Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].Bcl-2抑制剂维奈克拉联合方案治疗30例IDH1/2突变急性髓系白血病的临床分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):691-694. doi: 10.3760/cma.j.issn.0253-2727.2022.08.014.
10
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.ABT-199 选择性抑制 BCL-2 导致急性髓系白血病的靶细胞死亡。
Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.

引用本文的文献

1
Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia.在老年急性髓系白血病患者中使用选择性BCL-2抑制剂进行靶向治疗。
Hematol Transfus Cell Ther. 2019 Apr-Jun;41(2):169-177. doi: 10.1016/j.htct.2018.09.001. Epub 2018 Dec 29.

本文引用的文献

1
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.异柠檬酸脱氢酶1和2突变在急性髓系白血病中诱导对BCL-2的依赖性。
Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19.
2
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.人类急性髓系白血病中的白血病前期突变影响表观遗传调节剂，并在缓解期持续存在。
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53. doi: 10.1073/pnas.1324297111. Epub 2014 Feb 3.
3
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
靶向抑制白血病细胞中的突变 IDH2 诱导细胞分化。
Science. 2013 May 3;340(6132):622-6. doi: 10.1126/science.1234769. Epub 2013 Apr 4.
4
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.一种突变 IDH1 抑制剂可延缓神经胶质瘤细胞的生长并促进其分化。
Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.
5
Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia.急性髓系白血病中线粒体 DNA 变异的特征及预后意义。
Eur J Haematol. 2013 May;90(5):385-96. doi: 10.1111/ejh.12090. Epub 2013 Mar 22.
6
Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.简明综述：白血病前体细胞——白血病干细胞前体的分子生物学和临床意义。
Stem Cells Transl Med. 2013 Feb;2(2):143-50. doi: 10.5966/sctm.2012-0109. Epub 2013 Jan 24.
7
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.ABT-199，一种强效和选择性的 BCL-2 抑制剂，在发挥抗肿瘤活性的同时不影响血小板。
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
8
Spectrum of somatic mitochondrial mutations in five cancers.五种癌症中线粒体体突变的频谱。
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14087-91. doi: 10.1073/pnas.1211502109. Epub 2012 Aug 13.
9
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.白血病 IDH1 和 IDH2 突变导致超甲基化表型，破坏 TET2 功能，并损害造血分化。
Cancer Cell. 2010 Dec 14;18(6):553-67. doi: 10.1016/j.ccr.2010.11.015. Epub 2010 Dec 9.
10
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.白血病相关 IDH1 和 IDH2 突变的共同特征是一种新的酶活性，可将α-酮戊二酸转化为 2-羟基戊二酸。
Cancer Cell. 2010 Mar 16;17(3):225-34. doi: 10.1016/j.ccr.2010.01.020. Epub 2010 Feb 18.